|
|
|
| Interpretation of Clinical Guidelines for Irritable Bowel Syndrome issued by American Gastroenterology Association, 2020 and comparison of diagnosis and treatment in China and the United States#br# |
| GU Haoran BIAN Zhaolian |
| Department of Gastroenterology, Nantong Third People’s Hospital, Jiangsu Province, Nantong 226000, China |
|
|
|
Abstract Irritable bowel syndrome (IBS), as a refractory functional gastrointestinal disease, has brought huge economic burden to medical systems of various countries in the world. The American College of Gastroenterology (ACG) recently updated its guidelines for the diagnosis and treatment of IBS, adopting the GRADE grading method for the first time to analyze the management of IBS from two aspects of diagnosis and treatment. Chinese scholars have also carried out a lot of studies. According to specific national conditions of China, Delphi program is adopted to update the IBS expert consensus. This paper aims to interpret the ACG 2020 Clinical Guidelines for Irritable Bowel Syndrome and make a comparative analysis with the Expert Consensus On Irritable Bowel Syndrome in China in 2020, in order to provide reference for the diagnosis and treatment of patients with IBS in China.
|
|
|
|
|
|
[1] Ford AC，Lacy BE，Talley NJ. Irritable bowel syndrome [J]. N Eng J Med，2017，376（26）：2566-2578.
[2] Mearin F，Lacy BE，Chang L，et al. Bowel Disorders [J]. Gastroenterology，2016，150：1393-1407.
[3] Palsson OS，Whitehead W，T?觟rnblom H，et al. Prevalence of Rome IV functional bowel disorders among adults in the United States，Canada and United Kingdom [J]. Gastroenterology，2020，158（5）：1262-1273.e3.
[4] Sperber AD，Bangdiwala SI，Drossman DA，et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders，Results of Rome Foundation Global Study -ScienceDirect [J]. Gastroenterology，2021，160（1）：99-114.e3.
[5] Canavan C，West J，Card T. Review article：The economic impact of the irritable bowel syndrome [J]. Aliment Pharmacol Ther，2014，40（9）：1023-1034.
[6] 中华医学会消化病学分会胃肠功能性疾病协作组，中华医学会消化病学分会胃肠动力学组. 2020年中国肠易激综合征专家共识意见[J].中华消化杂志，2020，40（12）：803-818.
[7] Mein SM，Ladabaum U. Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome： a cost-effectiveness analysis [J]. Aliment Pharmacol Ther，2015，19（11）：1199-1210.
[8] Whitehead WE，Palsson OS，Feld AD，et al. Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome [J]. Aliment Pharmacol Ther，2006，24（1）：137-146.
[9] Van Rheenen PF，Van de Vijver E，Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease：Diagnostic meta-analysis [J]. BMJ，2010，341：c3369.
[10] Sidhu R，Wilson P，Wright A，et al. Faecal lactoferrin：A novel test todifferentiate between the irritable and inflamed bowel [J]. Aliment Pharmacol Ther，2010，31（12）：1365-1370.
[11] Klem F，Wadhwa A，Prokop LJ，et al. Prevalence，risk factors，and outcomes of irritable bowel syndrome after infectious enteritis：A systematic review and meta-analysis [J]. Gastroenterology，2017，152（5）：1042-1054.
[12] Begtrup LM，Engsbro AL，Kjeldsen J，et al. A Positive Diagnostic Strategy Is Noninferior to a Strategy of Exclusion for Patients With Irritable Bowel Syndrome [J]. Clin Gastroenterol Hepatol，2013，11（8）：956-962.e1.
[13] Spiegel BMR，Farid M，Esrailian E，et al. Is Irritable Bowel Syndrome a Diagnosis of Exclusion：A Survey of Primary Care Providers，Gastroenterologists，and IBS Experts [J]. Am J Gastroenterol，2010，105（4）：848-858.
[14] Eswaran SL，Chey WD，Han-Markey T，et al. A randomized controlled trial comparing the low FODMAP diet vs.modified NICE guidelines in US with IBS-D [J]. Am J Gastroenterol，2016，111（12）：1824-1832.
[15] Weerts ZZ，Masclee AAM，Witteman BJM，et al. Efficacy and safety of peppermint oil in a randomized，double-blink trial of patients with IBS [J]. Gastroenterol，2020， 158（1）：123-136.
[16] Johanson JF，Drossman DA，Panas R，et al. Clinical trial：Phase 2 study of lubiprostone for irritable bowel syndrome with constipation [J]. Aliment Pharmacol Ther，2008，27（8）：685-696.
[17] Pimentel M，Lembo A，Chey WD，et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation [J]. N Engl J Med，2011，364（1）：22-32.
[18] US FDA. Lotronex （alosetron hydrochloride）Information [Z]. Updated January 6，2016. Accessed November 23，2020. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/lotronex-alosetron-hydrochloride-information.
[19] Wade PR，Palmer JM，KcKenney S，et al. Modulation of gastrointestinal function by MuDelta，a mixed mu opioid receptor agonist/delta opioid receptor antagonist [J]. Br J Pharmacol，2012，167（5）：1111-1125.
[20] Brenner DM，Sayuk GS，Gutman CR，et al. Efficacy and safety of eluxadoline in patients with irritable bowel syndrome with diarrhea who report inadequate symptom control with loperamide：RELIEF phase 4 study [J]. Am J Gastroenterol，2019，114（9）：1502-1511.
[21] Van Oudenhove L，Levy RL，Crowell MD，et al. Biopsychosocial aspects of functional gastrointestinal disorders [J]. Gastroenterology，2016，150：1355-1367.
[22] Xu D，Chen VL，Steiner CA，et al. Efficacy of fecal microbiota transplantation in irritable bowel syndrome：A systematic review and meta-analysis [J]. Am J Gastroenterol，2019，114（7）：1043-1050.
[23] Xiong L，Gong X，Siah TH，et al. Rome foundation Asian working team report：Real world treatment experience of Asian patients with functional bowel disorders [J]. J Gastroenterol Hepatol，2017，32（8）：1450-1456.
[24] Hungin A，Whorwell PJ，Tack J，et al. The prevalence，patterns and impact of irritable bowel syndrome：An international survey of 40，000 subjects [J]. Aliment Pharmacol Ther，2003，17（5）：643-650.
[25] Xiong LS，Chen MH，Chen HX，et al. A population-based epidemiologic study of irritable bowel syndrome in South China：stratified randomized study by cluster sampling [J]. Aliment Pharmacol Ther，2004，19（11）：1217-1224. |
|
|
|
